Literature DB >> 10805104

Clinical validity of Braak neuropathological staging in the oldest-old.

G Gold1, C Bouras, E Kövari, A Canuto, B G Glaría, A Malky, P R Hof, J P Michel, P Giannakopoulos.   

Abstract

Several studies have demonstrated a good correlation between clinical severity and Braak's neuropathological staging in Alzheimer's disease (AD). However, nonagenarians and centenarians display a different pattern of cortical vulnerability to the neurodegenerative process compared to younger elderly, and it is not known whether correlations between clinical severity and neuropathological stages remain valid in this age group. To address this issue we compared Clinical Dementia Rating scale (CDR) scores and Braak stages in 116 patients over 90 years of age with either no cognitive impairment or very mild to severe AD. There is a strong positive correlation between CDR scores and Braak staging (Spearman coefficient = 0.66; P < 0.01). However, neuropathological staging does not distinguish cases with normal cognition (CDR 0) from those with mild cognitive changes (CDR 0.5). Unlike younger cohorts, Braak stages I and II are frequently associated with questionable dementia in this age group. Braak stage III overlaps with all CDR levels and correlates poorly with cognitive function. Braak stages IV or greater are consistently associated with at least mild dementia. Consistent with our previous neuropathological analyses of nonagenarians and centenarians, the present data suggest that the substantial involvement of the hippocampus which characterizes Braak stage IV is a key step in the development of overt clinical signs of dementia in the oldest-old. Moreover, they indicate that Braak staging represents a broad concept of the evolution of neurofibrillary tangles rather than a precise hierarchical model associated with a stepwise deterioration of cognitive abilities near the upper limit of life.

Entities:  

Mesh:

Year:  2000        PMID: 10805104     DOI: 10.1007/s004010051163

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  40 in total

1.  Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old.

Authors:  John L Robinson; Felix Geser; Maria M Corrada; Daniel J Berlau; Steven E Arnold; Virginia M-Y Lee; Claudia H Kawas; John Q Trojanowski
Journal:  Brain       Date:  2011-11-26       Impact factor: 13.501

2.  Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment.

Authors:  Elliott J Mufson; Michael Malek-Ahmadi; Sylvia E Perez; Kewei Chen
Journal:  Neurobiol Aging       Date:  2015-10-20       Impact factor: 4.673

3.  Activation of caspase-6 in aging and mild cognitive impairment.

Authors:  Steffen Albrecht; Martine Bourdeau; David Bennett; Elliott J Mufson; Meena Bhattacharjee; Andréa C LeBlanc
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

4.  Screening of Synthetic Isoxazolone Derivative Role in Alzheimer's Disease: Computational and Pharmacological Approach.

Authors:  Meissam Ali; Uzma Saleem; Fareeha Anwar; Muhammad Imran; Humaira Nadeem; Bashir Ahmad; Tahir Ali; Tariq Ismail
Journal:  Neurochem Res       Date:  2021-01-24       Impact factor: 3.996

Review 5.  The impact of vascular burden on late-life depression.

Authors:  Micaela Santos; Enikö Kövari; Patrick R Hof; Gabriel Gold; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  Brain Res Rev       Date:  2009-09-08

Review 6.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

Review 7.  Cognitive reserve in aging.

Authors:  A M Tucker; Y Stern
Journal:  Curr Alzheimer Res       Date:  2011-06       Impact factor: 3.498

8.  Clinico-Neuropathological Findings in the Oldest Old from the Georgia Centenarian Study.

Authors:  Jirayu Tanprasertsuk; Elizabeth J Johnson; Mary Ann Johnson; Leonard W Poon; Peter T Nelson; Adam Davey; Peter Martin; Aron K Barbey; Kathryn Barger; Xiang-Dong Wang; Tammy M Scott
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

9.  Multiregional Age-Associated Reduction of Brain Neuronal Reserve Without Association With Neurofibrillary Degeneration or β-Amyloidosis.

Authors:  Jerzy Wegiel; Michael Flory; Izabela Kuchna; Krzysztof Nowicki; Shuang Yong Ma; Jarek Wegiel; Eulalia Badmaev; Wayne P Silverman; Mony de Leon; Barry Reisberg; Thomas Wisniewski
Journal:  J Neuropathol Exp Neurol       Date:  2017-06-01       Impact factor: 3.685

Review 10.  Alzheimer disease therapy--moving from amyloid-β to tau.

Authors:  Ezio Giacobini; Gabriel Gold
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.